August 31, 2022 Talat Imran VIA EMAIL Re: Amended and Restated Employment Agreement Dear Talat:Rani Therapeutics Holdings, Inc. • March 22nd, 2023 • Pharmaceutical preparations
You are currently employed by RANI MANAGEMENT SERVICES, INC. (“RMS”) under the terms of an employment agreement between you and RMS dated June 17, 2021 (the “ RMS Agreement”). Your employment is being transitioned from RMS to Rani Therapeutics, LLC (the “Company”) effective as of September 1, 2022 (the “Transition Date”). Once you accept this employment agreement (the “Agreement”) by signing and returning it to the Company, this Agreement shall supersede and replace the RMS agreement in its entirety. This Agreement, together with the other documents and agreements referenced herein, shall then govern the terms of your employment with the Company.
License and Supply Agreement By and Between Rani Therapeutics, LLC and Celltrion, Inc. Dated January 6, 2023License and Supply Agreement • March 22nd, 2023 • Rani Therapeutics Holdings, Inc. • Pharmaceutical preparations • Delaware
This License and Supply Agreement (this “Agreement”), effective as of January 6, 2023 (the “Effective Date”), is by and between Rani Therapeutics, LLC, a California limited liability company having an address at 2051 Ringwood Ave., San Jose, California 95131, USA (“Rani”), and Celltrion, Inc., having an address at 23, Academy-ro, Yeonsu-gu, Incheon, 22014, Republic of Korea (“Celltrion”). Rani and Celltrion are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
